Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | |
| hours per response: | . 0.5 | | | | | | | |

| STATEMENT | OF (| СНА | NGE | S II | N B | ENI | EFIC | IAL (| OWNERSHI | Ρ |
|-----------|------|-----|-----|------|-----|-----|------|-------|----------|---|
| | | | | | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

| | Idress of Reporting | 0 | 2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT] | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | |
|-----------------------------------|---------------------|---------------|--|------------------|---|-----------------------|--|--|--|
| Watanabe Todd Franklin | | | <u></u> | X | Director | 10% Owner | | | |
| (Last) (First) (Middle) | | (Middle) | Dete of Earliest Transaction (Marsh/Dev(Marsh) | _ x | Officer (give title below) | Other (specify below) | | | |
| C/O ARCUTIS BIOTHERAPEUTICS, INC. | | PEUTICS, INC. | 3. Date of Earliest Transaction (Month/Day/Year) 06/06/2022 | | President and | d CEO | | | |
| 3027 TOWN | SGATE ROAD | 9, SUITE 300 | | | | | | | |
| (Street) | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indi Line) | vidual or Joint/Group Fili | ing (Check Applicable | | | |
| WESTLAKE CA 91361 | | 91361 | | X | Form filed by One Reporting Person | | | | |
| VILLAGE | | | _ | | Form filed by More th Person | an One Reporting | | | |
| (City) | (State) | (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---|------------------------------|---|--------|---------------|-------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150.4) |
| Common Stock | 06/06/2022 | | S ⁽¹⁾ | | 1,000 | D | \$21.064(2) | 659,284 ⁽³⁾⁽⁴⁾ | D | |
| Common Stock | | | | | | | | 57,358 | Ι | By LLC ⁽⁵⁾ |
| Common Stock | | | | | | | | 17,850 | Ι | By Trust ⁽⁶⁾ |
| Common Stock | | | | | | | | 17,850 | Ι | By Trust ⁽⁷⁾ |
| Common Stock | | | | | | | | 124,956 | Ι | By Trust ⁽⁸⁾ |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | (c.g., puts, cuits, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|--|-----|----------------------|--------------------|--|--|--|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | ation Date Amount of | | Amount of Securities Derivative Securities derivative Securities Underlying Derivative Security (Instr. 5) Beneficially Owned Following Reported | | Securities Beneficially Owned Following Reported Transaction(s) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

2. The transaction was executed in multiple trades in prices ranging from \$20.84 to \$21.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote

3. Reflects the adjusted total which includes the purchase of 1,617 shares under the Arcutis Employee Stock Purchase Plan on May 31, 2022.

4. Includes 109,925 restricted stock units.

5. The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

6. The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities or purposes of Section 16 or for any other purposes.

7. The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities of Section 16 or for any other purposes

8. The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

> /s/ Scott Burrows, as Attorney-in-Fact for Todd Franklin Watanabe ** Signature of Reporting Person

06/06/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.